Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | PKM | P14618 | 3/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.51 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.51 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MPO | P05164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5737641 | 0.86 | KDM4E (0.49) | LMNAKDM4EPKMADORA3ADORA2A | |
| SCHEMBL22460013 | 0.84 | KDM4E (0.41) | LMNAKDM4EPKMADORA3ADORA2A | |
| SCHEMBL12713296 | 0.83 | KDM4E (0.49) | LMNAKDM4EPKMADORA3ADORA2A | |
| SCHEMBL24701303 | 0.82 | CYP3A4 (0.48) | LMNAKDM4EPKMADORA3ADORA2A | |
| SCHEMBL19283247 | 0.82 | NPC1 (0.44) | LMNAKDM4ECYP3A4TSHRSMN1; SMN2 | |
| SCHEMBL24701098 | 0.82 | TP53 (0.46) | LMNAKDM4EPKMCYP3A4TSHR | |
| SCHEMBL3507658 | 0.81 | KDM4E (0.51) | LMNAKDM4EPKMADORA3ADORA2A | |
| SCHEMBL3520487 | 0.81 | KDM4E (0.48) | LMNAKDM4EPKMADORA3ADORA2A | |
| SCHEMBL7148312 | 0.81 | SMN1; SMN2 (0.49) | KDM4ESMN1; SMN2P2RX7HPGDTP53 | |
| SCHEMBL203832 | 0.81 | KDM4E (0.48) | LMNAKDM4EPKMADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179008-A1 | ANTIBACTERIAL AGENTS | TAXIS PHARMACEUTICALS, INC. (US) | 2025-06-05 | — | — | US | disclosed |
| US-11691992-B2 | Oxaborole analogs and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20220402883-A1 | COMPOUNDS AND METHODS FOR MODULATING RNA FUNCTION | ARRAKIS THERAPEUTICS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-20220281860-A1 | COMPOUNDS AND METHODS OF TREATING RNA-MEDIATED DISEASES | ARRAKIS THERAPEUTICS, INC. | 2022-09-08 | — | — | US | disclosed |
| US-10961261-B2 | Oxaborole analogs and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-9920075-B2 | Triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-03-20 | — | — | US | disclosed |
| EP-2914597-B1 | PYRAZOLOPYRIDINE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC (JP) | 2017-12-06 | — | — | EP | disclosed |
| US-20170247396-A1 | TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2017-08-31 | — | — | US | disclosed |
| EP-3191485-A1 | TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE | Bristol-Myers Squibb Company (US) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016040417-A1 | TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-17 | — | — | WO | disclosed |
| US-7470807-B2 | Suppress production of both prostaglandins and leukotrienes and have reduced side effects; treatment of various inflammatory diseases, autoimmune diseases, allergic diseases, pain and fibrosis; for example, methyl 3-[3-acetylamino-4-cyclopentyloxy-5-(naphthalen-2-yl)phenyl]propionate | ASAHI KASEI PHARMA CORPORATION (JP) | 2008-12-30 | — | — | US | disclosed |
| EP-1996180-A1 | ANTIBACTERIAL AGENTS | Prolysis Limited (GB) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007107758-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007107758-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2007-09-27 | — | — | WO | disclosed |
| US-20070213333-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHAMA CORPORATION (JP) | 2007-09-13 | — | — | US | disclosed |
| US-20070213333-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHAMA CORPORATION (JP) | 2007-09-13 | — | — | US | disclosed |
| US-6642234-B1 | Insecticides, acaricides, nematocides, herbicides and fungicides, | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2003-11-04 | — | — | US | disclosed |
| EP-1142882-A9 | ACRYLONITRILE COMPOUNDS | Nissan Chemical Industries, Ltd. (JP) | 2002-10-02 | — | — | EP | disclosed |
| CN-1333759-A | Acrylonitrile compounds | NISSAN CHEMICAL IND LTD (JP) | 2002-01-30 | — | — | CN | disclosed |
| EP-1142882-A1 | ACRYLONITRILE COMPOUNDS | Nissan Chemical Industries, Ltd. (JP) | 2001-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247396-A1 | TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE | EPX, MPO, SERPINB1 | LMNA 4689/4885KDM4E 1797/4885PKM 1675/4885 |
| US-11691992-B2 | Oxaborole analogs and uses thereof | OXA1L, EPX, OAT | LMNA 2380/4885KDM4E 3901/4885PKM 2208/4885 |
| US-20220281860-A1 | COMPOUNDS AND METHODS OF TREATING RNA-MEDIATED DISEASES | NSUN3, NSUN2, POLRMT | LMNA 434/4885KDM4E 1266/4885PKM 1810/4885 |
| US-10961261-B2 | Oxaborole analogs and uses thereof | OXA1L, EPX, OAT | LMNA 2380/4885KDM4E 3901/4885PKM 2208/4885 |
| US-20220402883-A1 | COMPOUNDS AND METHODS FOR MODULATING RNA FUNCTION | NSUN3, NSUN2, METTL16 | LMNA 1551/4885KDM4E 1087/4885PKM 1945/4885 |
| US-20250179008-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | LMNA 1817/4885KDM4E 2407/4885PKM 3434/4885 |
| US-20070213333-A1 | Substituted arylalkanoic acid derivatives and use thereof | CYSLTR1, CYSLTR2, LTB4R2 | LMNA 1846/4885KDM4E 1472/4885PKM 2058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.